NeuroSense Therapeutics’ investigational therapy PrimeC tends to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve…
Articles by Lindsey Shapiro, PhD
While the now-discontinued amyotrophic lateral sclerosis (ALS) therapy Relyvrio (sodium phenylbutyrate and taurursodiol) failed to show a meaningful…
Storing chemicals such as gasoline, lawn care products, and paints in a garage attached to a home was associated with…
The U.S. Food and Drug Administration (FDA) has agreed on the design of a Phase 3b trial that will test…
SLS-005 did not significantly slow amyotrophic lateral sclerosis (ALS) progression compared with a placebo in the HEALEY platform…
Brain Trust Bio (BTB) has been cleared to launch Phase 1 clinical trials in Australia to test the efficacy…
A biomarker test that identifies abnormal protein fragments called cryptic peptides may help detect amyotrophic lateral sclerosis (ALS) and…
When investigational amyotrophic lateral sclerosis (ALS) therapy CNM-Au8 reaches the bloodstream, it attracts a layer of proteins called a…
Treatment with CNM-Au8 was shown to significantly prolong survival — relative to the natural history of the disease —…
Denali Therapeutics’ SAR443820 (DNL788) treatment candidate — now in late-stage clinical testing for amyotrophic lateral sclerosis (ALS), per the…